开盘价:-- | 最高价:-- | 最低价:-- | 52周最高价:-- | 52周最低价:-- |
成交量:-- | 平均成交量:-- | 市值:-- | 市盈率:-- | 预期市盈率:-- |
每股收益:-- | 贝塔系数:-- | 股息:-- | 收益率:-- | 总股本:-- |
证券代码:lmnl | 公司名称:Liminal BioSciences, Inc. | 公司中文简称: |
公司简介: Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada. |
||
公司网站: http://www.liminalbiosciences.com |
||
公司地址: 440, boulevard Armand-Frappier Suite 300 Laval |